Business Context and Reporting Period
Zenas Biopharma, Inc. (ZBIO), a Delaware corporation and emerging growth company, filed this Form 8-K on March 26, 2026, reporting events occurring on March 26 and March 31, 2026. The filing details the completion of two simultaneous capital raising transactions: a Convertible Notes Offering and an Equity Offering.
Key Financial Metrics and Capital Structure
- Convertible Notes Offering: Issued $200,000,000 aggregate principal amount of 2.50% Convertible Senior Notes due 2032. Net proceeds were approximately $193.7 million.
- Equity Offering: Issued 5,000,000 shares of Common Stock at $20.00 per share. Net proceeds were approximately $93.7 million.
- Total Net Proceeds: Approximately $287.4 million combined from both offerings.
- Debt Terms: Notes bear interest at 2.50% per year, payable semiannually starting October 1, 2026. Maturity date is April 1, 2032.
- Conversion Terms: Initial conversion rate is 37.7358 shares per $1,000 principal amount (approx. $26.50 conversion price). Maximum potential issuance upon conversion is 11,500,000 shares based on the maximum conversion rate.
- Over-Allotment Options: Underwriters hold a 30-day option to purchase up to an additional $30.0 million in Notes and 750,000 shares of Common Stock.
Material Changes and Use of Proceeds
The primary material change is the significant increase in liquidity and debt obligations resulting from the March 31, 2026 closing of the offerings. The company intends to use the net proceeds to:
- Support the planned U.S. commercial launch of obexelimab for IgG4-RD (if approved).
- Advance the development pipeline, including orelabrutinib Phase 3 trials for progressive multiple sclerosis.
- Fund ZB021 Phase 1 and Phase 2 clinical development.
- Provide working capital and general corporate purposes.
Outlook, Risks, and Contingencies
Management faces significant risks regarding the company's financial stability and operational execution. Key contingencies include:
- Going Concern Doubt: The company's independent registered public accounting firm has expressed substantial doubt about Zenas Biopharma's ability to continue as a going concern in its 2025 Annual Report (Form 10-K).
- Operating Losses: The company has incurred substantial losses since inception and anticipates incurring substantial and increasing losses for the foreseeable future.
- Clinical and Regulatory Risk: Success depends on the uncertain outcomes of clinical trials and regulatory approvals for obexelimab, orelabrutinib, and ZB021.
- Supply Chain Risk: The company relies on a sole contract manufacturing organization, WuXi Biologics (Hong Kong) Limited, located in China, exposing it to geopolitical and trade risks.
- Debt Covenants: The Notes contain customary events of default, including payment defaults, failure to file reports, and bankruptcy events. Special interest may accrue if reporting covenants are breached.
Investor Verification Checklist
- Verify the exact closing date and final net proceeds of both the Convertible Notes and Equity Offerings in the final closing documents.
- Review the "Risk Factors" section of the most recent Form 10-K for details on the "substantial doubt" regarding the company's ability to continue as a going concern.
- Confirm the status of the over-allotment options (30-day window) and whether underwriters have exercised them.
- Monitor the company's ability to meet the semiannual interest payment obligations starting October 1, 2026.
- Assess the timeline and regulatory status of the obexelimab commercial launch and orelabrutinib Phase 3 trials to validate the use of proceeds.